Horizon Pharma Inc. (NASDAQ:HZNP)‘s stock had its “buy” rating reiterated by stock analysts at Mizuho in a report issued on Tuesday. They currently have a $33.00 price objective on the biopharmaceutical company’s stock. Mizuho’s target price suggests a potential upside of 69.06% from the stock’s previous close.
A number of other equities analysts have also recently weighed in on the stock. Vetr raised shares of Horizon Pharma from a “buy” rating to a “strong-buy” rating in a research report on Monday, October 3rd. Stifel Nicolaus reissued a “buy” rating and set a $45.00 price target on shares of Horizon Pharma in a research report on Wednesday, July 6th. Guggenheim reissued a “buy” rating and set a $30.00 price target on shares of Horizon Pharma in a research report on Tuesday, August 23rd. Morgan Stanley raised shares of Horizon Pharma from an “underweight” rating to an “equal weight” rating and set a $24.00 price objective on the stock in a research report on Monday, July 11th. Finally, Brean Capital reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Horizon Pharma in a research report on Thursday, July 14th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Horizon Pharma presently has an average rating of “Buy” and a consensus price target of $30.00.
Horizon Pharma (NASDAQ:HZNP) traded down 6.56% during trading on Tuesday, reaching $18.24. 7,491,568 shares of the company’s stock traded hands. The firm has a 50 day moving average price of $19.05 and a 200-day moving average price of $17.85. Horizon Pharma has a 12 month low of $12.86 and a 12 month high of $23.70. The firm’s market cap is $2.93 billion.
Horizon Pharma (NASDAQ:HZNP) last announced its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported $0.62 earnings per share for the quarter, topping analysts’ consensus estimates of $0.50 by $0.12. The company had revenue of $257.40 million for the quarter, compared to analysts’ expectations of $235.43 million. Horizon Pharma had a negative net margin of 0.34% and a positive return on equity of 23.46%. The business’s quarterly revenue was up 48.9% compared to the same quarter last year. During the same period last year, the firm posted $0.39 earnings per share. On average, analysts forecast that Horizon Pharma will post $2.15 earnings per share for the current fiscal year.
In other news, EVP Jeffrey W. Sherman sold 2,900 shares of the business’s stock in a transaction dated Tuesday, August 2nd. The shares were sold at an average price of $20.00, for a total transaction of $58,000.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders own 2.10% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Virginia Retirement System purchased a new position in Horizon Pharma during the first quarter valued at $282,000. Franklin Resources Inc. raised its position in shares of Horizon Pharma by 5,195.9% in the first quarter. Franklin Resources Inc. now owns 1,276,730 shares of the biopharmaceutical company’s stock worth $21,155,000 after buying an additional 1,252,622 shares during the period. BlackRock Group LTD raised its position in shares of Horizon Pharma by 21.0% in the first quarter. BlackRock Group LTD now owns 100,919 shares of the biopharmaceutical company’s stock worth $1,672,000 after buying an additional 17,505 shares during the period. BlackRock Fund Advisors raised its position in shares of Horizon Pharma by 7.6% in the first quarter. BlackRock Fund Advisors now owns 2,937,687 shares of the biopharmaceutical company’s stock worth $48,677,000 after buying an additional 208,391 shares during the period. Finally, BlackRock Institutional Trust Company N.A. raised its position in shares of Horizon Pharma by 2.7% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 2,337,953 shares of the biopharmaceutical company’s stock worth $38,740,000 after buying an additional 61,457 shares during the period. Institutional investors own 85.25% of the company’s stock.
Horizon Pharma Company Profile
Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products. It markets approximately nine medicines through its orphan, primary care and rheumatology business units.
Receive News & Ratings for Horizon Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.